Stuart A. Arbuckle - 16 Feb 2024 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, COO
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
16 Feb 2024
Net transactions value
-$5,347,712
Form type
4
Filing time
21 Feb 2024, 16:19:22 UTC
Previous filing
12 Feb 2024
Next filing
23 Feb 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Tax liability $1,907,621 -4,499 -5.9% $424.01 71,219 16 Feb 2024 Direct
transaction VRTX Common Stock Tax liability $1,418,616 -3,373 -4.7% $420.58 67,846 20 Feb 2024 Direct
transaction VRTX Common Stock Sale $2,021,475 -4,804 -7.1% $420.79 63,042 20 Feb 2024 Direct F1
holding VRTX Common Stock 140 16 Feb 2024 401(k)
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023.